Pulse Biosciences (NASDAQ:PLSE) Trading Down 7.8% – Here’s Why

Shares of Pulse Biosciences, Inc. (NASDAQ:PLSE) were down 7.8% during mid-day trading on Wednesday . The company traded as low as $20.46 and last traded at $20.18. Approximately 125,583 shares traded hands during mid-day trading, a decline of 16% from the average daily volume of 149,235 shares. The stock had previously closed at $21.89.

Wall Street Analysts Forecast Growth

Separately, StockNews.com raised Pulse Biosciences to a “sell” rating in a research report on Thursday, January 2nd.

Pulse Biosciences Price Performance

The company’s 50 day moving average is $19.33 and its 200-day moving average is $18.31.

Insider Transactions at Pulse Biosciences

In other Pulse Biosciences news, CEO Burke Thomas Barrett sold 50,000 shares of the firm’s stock in a transaction dated Wednesday, December 11th. The shares were sold at an average price of $17.42, for a total transaction of $871,000.00. Following the completion of the sale, the chief executive officer now directly owns 63,172 shares in the company, valued at approximately $1,100,456.24. This trade represents a 44.18 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Robert W. Duggan purchased 55,256 shares of the business’s stock in a transaction dated Friday, December 13th. The shares were purchased at an average price of $17.18 per share, for a total transaction of $949,298.08. Following the acquisition, the director now owns 42,328,717 shares of the company’s stock, valued at approximately $727,207,358.06. The trade was a 0.13 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders own 71.50% of the company’s stock.

Hedge Funds Weigh In On Pulse Biosciences

Hedge funds and other institutional investors have recently modified their holdings of the company. Tower Research Capital LLC TRC increased its position in Pulse Biosciences by 98.1% during the fourth quarter. Tower Research Capital LLC TRC now owns 1,692 shares of the company’s stock valued at $29,000 after acquiring an additional 838 shares during the last quarter. KLP Kapitalforvaltning AS purchased a new stake in shares of Pulse Biosciences during the 4th quarter valued at about $44,000. Caisse Des Depots ET Consignations bought a new position in shares of Pulse Biosciences in the 4th quarter worth approximately $95,000. Farther Finance Advisors LLC boosted its holdings in shares of Pulse Biosciences by 44.4% in the fourth quarter. Farther Finance Advisors LLC now owns 7,220 shares of the company’s stock worth $126,000 after buying an additional 2,220 shares during the last quarter. Finally, SG Americas Securities LLC bought a new stake in Pulse Biosciences during the fourth quarter valued at approximately $193,000. 76.95% of the stock is owned by institutional investors.

About Pulse Biosciences

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.